This article is more than 5 years old. Information may no longer be current.

I-Therapeutix closes $15 million in Series C funding

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WALTHAM, Mass. — I-Therapeutix has secured $15 million in Series C financing from Polaris Venture Partners and existing investors Versant Ventures and SV Life Sciences, I-Therapeutix announced in a press release.

The company plans to use these funds to commercialize its I-Zip Ocular Bandage in the United States and to develop sustained drug delivery platforms for treating ophthalmic diseases and infections, the release said.

The I-Zip ocular bandage has already gained CE Mark approval and is currently undergoing pivotal clinical testing in the U.S.